| Name | S-nitrosoglutathione |
|---|---|
| Synonyms |
N-(N-L-gama-glutamyl-S-nitroso-L-cysteinyl)glycine
(2S)-2-amino-5-[[(1R)-2-(cboxymethylamino)-1-(nitrososulfanylmethyl)-2-oxo-ethyl]amino]-5-oxo-pentanoic acid (2S)-2-amino-5-[[(2R)-1-(cboxymethylamino)-3-nitrososulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid S-Nitrosoglutathione S-NITROSOGLUTATHIONE S-Nitrosoglutatione Talabostat Impurity 27 S-Nitroso-L-glutathioneGSNO GSNO, SNOG nitrosoglutathione γGlu-S-Nitroso-Cys-Gly-OH RVC 588 (ptide) S-Nitrosoglutathione - - Calbiochem S-NITROSO-L-GLUTATHIONE n-(n-l-gamma-glutamyl-2-nitroso-l-cysteinyl)-glycin S-Nitrosylglutathione nitrosoglutathione(GSNO) N-(N-L-GAMMA-GLUTAMYL-S-NITROSO-L-CYSTEINYL)-GLYCINE S-Nitroso-L-glutathione N-(N-L-g-Glutamyl-S-nitroso-L-cysteinyl)glycine MFCD00214341 EINECS 248-170-7 L-γ-GlutaMyl-S-nitroso-L-cysteinyl-glycine N-(N-L-γ- Glutamyl-S-nitroso -L-cysteinyl)glycine (S)-2-amino-5-(((R)-1-((cboxyMethyl)amino)-3-(nitrosothio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid S-Nitrosoglutathione (SNOG), NO donor L-γGlu-S-Nitroso-L-Cys-Gly-OH N-(N-L-GAMMA-GLUTAMYL-S-NITROSO-L-CYSTEINYL)GLYCINE (S-NITROSOGLUTATHIONE) Glycine, L-g-glutamyl-S-nitroso-L-cysteinyl Glycine, L-γ-glutamyl-S-nitroso-L-cysteinyl S-Nitrosoglutathione (GSNO) |
| Description | Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class III isoenzyme, inhibits cerebrovascular angiotensin II-dependent and -independent AT1 receptor responses[1][2][3][4]. |
|---|---|
| Related Catalog | |
| In Vitro | Nitrosoglutathione (GSNO, 250 μM) prevents 90% of the response to 0.1 μM 5-HT and 40% of the response to 1.0 μM 5-HT in rings treated with LY-83583, indicating an effect of GSNO that was independent of guanylate cyclase activity[5]. |
| In Vivo | Nitrosoglutathione (GSNO, 8 mg/kg) significantly decreases systolic, diastolic, and mean arterial pressures in PE-induced rats from day 14 through day 20[3]. Nitrosoglutathione (GSNO, 0.2 and 0.6 mg/kg) significantly inhibits superoxide production and suppressed NF-κB activation, iNOS induction, and 3-nitrotyrosine expression, butup-regulates endothelial NOS expression in the flap vessels[4]. Animal Model: Male Lewis rats[4]. Dosage: 0.2 and 0.6 mg/kg. Administration: Slow intravenous injection via the opposite femoral vein into each rat. Result: Animals treated with 0.2 mg of GSNO per kilogram before reperfusion had an intermediate survival rate (40.2 ± 4.9%). Although 0.6 mg/kg of GSNO showed a better rescuing effect than 150 mg/kg of NAC, there was no significant difference between the groups. |
| References |
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Melting Point | >170ºC (dec.) |
| Molecular Formula | C10H16N4O7S |
| Molecular Weight | 336.322 |
| Exact Mass | 336.073975 |
| PSA | 213.55000 |
| LogP | -0.26 |
| Index of Refraction | 1.656 |
| Storage condition | −20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATAMUTATION DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | MC0558000 |
| HS Code | 2930909090 |
| Precursor 9 | |
|---|---|
| DownStream 8 | |
| HS Code | 2930909090 |
|---|---|
| Summary | 2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |